chrisvoncsefalvay/vaers-outcomes huggingface dataset:
She got her vaccine, within 2 minutes her tongue starting tingling.  Then roughly a few minutes later she got such a dry mouth that she could not swallow her own saliva.  She went to the pharmacist and informed him that she was going into anaphylaxis and drank so much water that she had to use the bathroom.  She got home, took an allergy pill, and about 2 hours later her lips puffed up, they are still puffed up  She called her 24/7 nurse who talked to her for 30 minutes, asked a lot of questions and informed her that it was a typical path for an allergy to take and that within 2-3 hours she may get more symptoms, and to keep her Epi-Pen by her.  Suggested rinsing her mouth out with warm salt water and continued to drink water.  She then thinks her allergy pill kicked in, but continued to drink water.  She continued throughout the night with drinking water for the dry mouth.   Due to her allergies she has damage to her salivary glands and does have a dry mouth situation, but this was worse than her normal dry mouth.   She saw her doctor the next day and gave her a Kenalog shot and put her on oral steroids which she started today as pharmacy did not have it until today.  The Kenalog did make it easier to swallow with the dry mouth.  Her lips are still swollen and uncomfortable and very dry.   She is having anxiety over this.    She had the 1st J&J and the booster J&J and had no reactions to either one of them, not even a sore arm.    She had anaphylaxis that she has had in the past are to wasps, hornets, yellow jacket stings and has an Epi-Pen for that.  Her tongue swelled up badly with the wasp sting.  With the plum family fruit her larynx swelled up.    Wants to know what she can do for this, somebody in the CDC who she can talk to.
Information has been received from a nurse who reported that a patient reported that her "16 or 17 year old" female friend was vaccinated with a second dose of GARDASIL (Lot # not provided). Subsequently, she developed seizures and had to be taken to the hospital. Nurse reported that her patient reported that her friend also claimed that tests were performed in the hospital and the hospital physician felt her seizures were a result of GARDASIL and treated her with unspecified medications. The patient outcome was not provided. Upon internal review seizure was determined to be another important medical event. Attempts are being made to verify the existence of an identifiable patient and reporter. Additional information has been requested.
Patient said she got the flu from the flu shot she had yesterday. She still had fever at time of call and might go see physician at urgent care.
Information has been received from a pharmacist concerning a patient who on an unspecified date was vaccinated with a dose of PNEUMOVAX 23 vaccine (Lot # 664653/1337Y). Subsequently the patient experienced rash. At the time of this report, the patient's outcome was unknown. Follow-up information has been received from a pharmacist who reported that the 90 year old female patient with Coronary artery disease (CAD), depression, dementia, and no known allergies on 16-OCT-2010 was vaccinated into the right deltoid with a dose of PNEUMOVAX 23 vaccine. The patient had received a dose of influenza virus split virion 3v vaccine inactivated (manufacturer unknown) on 12-OCT-2010. The pharmacist also reported that on 17-OCT-2010, the patient had a rash on arm to elbow, afebrile. On an unspecified date the patient recovered. A standard lot check investigation has been finalized. All in-process quality checks for the lot number 664653/1337Y were satisfactory. In addition, an expanded lot check investigation was performed. The testing performed on the batch prior to release met all release specifications. The lot met the requirements of the agency and was released. This is one of several reports received from the same source. Follow-up information has been received concerning a 90 year old female patient with Coronary artery disease (CAD), Alzheimer, depression and dementia who on 16-OCT-2010 was vaccinated into the right deltoid with the first dose of PNEUMOVAX 23 vaccine (Lot # 664653/1337Y). Not known illness at time of vaccination. It was reported that on 17-OCT-2010, the patient experienced a localized reaction to right deltoid swollen and warm to touch (previously reported had a rash on arm to elbow, afebrile). A complete blood count (CBC) was performed on an unspecified date (results not reported). On an unspecified date the patient recovered. Right deltoid swollen and warm to touch was considered an other important medical event by the reporter due to required medical/surgical intervention to prevent one of the outcomes listed. No further information is available.
She got her vaccines, had the sore arm as expected.  She was told that she could not take any Ibuprofen which is the only pain medicine that works for her.  By 10:30 that night it came on very suddenly and was full into feeling bad, flu-like symptoms.  She took Alka-Seltzer night-time severe cold and flu, drank that and she was miserable with high fever but did not register it, was drenched with sweat and also suffers from hot flashes as she is going through menopause.  She then started having heart palpitations, and felt that it was from the Alka-Seltzer, but that feeling has never left her since stopping the medicine.  She gets them around her heart, feels tense and stressed.  She has a panic disorder also which she's having the reactions to the vaccine and the palpitations, which she cannot deal with it.  She has recently moved and as an APT in January and called to see what to do and was informed that she could treat her for that.  When she lies down she cannot breathe and also continues with the heart palpitations.  She went to the ER on 11/19/22 after her doctor said she could treat her, a friend felt that she may be having a heart attack.  She had an out patient sonogram who was informed by the tech that her heart was skipping a beat.  On 11/23/22 she called the doctors office to check and see what was going on as she was feeling like she was going to have a heart attack, and told her that everything was normal.  She has been feeling all the symptoms since she's had the vaccines.  The arm itself are fine, and the symptoms are "hell", she has the intermittent skipped beats, palpitations, and not feeling well.  The symptoms and the panic disorder are bouncing off each other and is not on any APT's to treat it.  she has an APT with the cardiologist on 12/2/22, and is not taking that there is nothing wrong with her as the symptoms are horrendous.  She had 2 very high BP readings in the ER, and due to the recent move she cannot get into a PCP sooner.   When she has the random reaction she gets pain, hollers with the pain, starts on the left, and then moves to the right and spreads around which triggers her anxiety.   She has a lot of back pain and feels like her lungs are hurting and feels like she has been kicked in the back on the back side of her heart, underneath the shoulder blade.  She also has a dull pain from her heart which like her heart is not relaxed.  She did have a chest x-ray and it was clear.  She feels like she is about to die, she is tired and feels real bad.  The cold sweats are scary too which is different from her menopause symptoms.  She does have elevated blood pressure, but is not on any BP medicine at this time and needs some relief from her symptoms.    She went to ER.  Her DC DX as chest pain, unspecific type and anxiety.
Child developed vomiting, severe hypotension, laryngospasm and wheezing within 10 minutes of vaccine. Given 2 epinephrine, O2 by mask and albuterol.
I started to experience a UTI and it was excruciating. I went through the pharmacy and had gotten the antibiotic KEFLEX. I was able to see my PCP on 07/20 and she kept KEFLEX, but moved me to a stronger dosage. I've never had frequent UTI's so I was surprised when this happened.
Pt started feeling weak within hours of vaccine progressive weakness ensued and pt began to have falls and Rapid decline in general status and Died 3- -2021
fever of 102 degrees F, shivering and chills, body aches, headache, malaise; symptoms lasted approximately 12 hours
flu- like symptoms; chills; headache; feeling bad; Sick; This case was reported by a pharmacist via call center representative and described the occurrence of influenza-like symptoms in an unspecified number of patients who received Flu Seasonal TIV Quebec (Flulaval) for prophylaxis.   On an unknown date, the patients received Flulaval. On an unknown date, unknown after receiving Flulaval, the patients experienced influenza-like symptoms, chills, headache, feeling bad and sickness. On an unknown date, the outcome of the influenza-like symptoms, chills, headache, feeling bad and sickness were unknown.   It was unknown if the reporter considered the influenza-like symptoms, chills, headache, feeling bad and sickness to be related to Flulaval.  Additional details were provided as follows: The age at vaccination was not applicable for this report. These symptoms occurred more frequently when vaccine was co-administered with Shingrix, than when the Flu vaccine was given alone. The reporter cannot quantify and had no further patient or product details. The reporter did not consent to follow-up. This case has been linked with case US2019063821, reported by same reporter.
Hives, skin rash, very mild fever of 99.1. Fever went away after 24 hours. Hives were on both arms and chest, skin was red, raised, itchy and irritated. Over-the-counter treatments reduced the rash but did not resolve after a week. Dermatologist prescribed topical steroid cream. Hives resolved and rash was gone within 5 days of treatment with prescribed cream.
Had hard time breathing and was congested and fatigued; Took a home COVID-19 test and it was positive; Contacted doctor and was prescribed PAXLOVID; Took another home COVID-19 test 2 weeks later and was negative.
To ER 10/12 4PM. Follow up at MD office 10/13/04. Significant erythema per mom, significant induration also on night prior.
Extreme headache from 2 hours after shot on Thursday night until midday Sunday (2 1/2 days), Several episodes of chills/shivering over 2 days, 2 hour period of fever of 100 degrees, increased productive coughing, gassiness and diarrhea.
24SEP93 reported by phone pt had fever of 101; advised by MD; not sleeping well, irritable, poor appetite pulling on ears; dx lt OM;
This spontaneous report was received from a currently 70 year old male patient. The patient did not have any allergies. Patient's medical history included cancer started on an unknown date in 1998 and 50 skin cancer surgeries between the years 1998 and 2012. The patient had spleen removed due to his cancer spreading on an unknown date in June 2012. The patient's concurrent condition included stage 4 Leukemia cancer and poor immune system. On an unknown date (reported as after the surgery), the patient was vaccinated with a dose of GARDASIL subcutaneous (dose, lot # and expiration date were not provided). Concomitant therapies included unspecified thyroid and statin medication. The patient stated that GARDASIL helped get rid of his stage 4 Leukemia cancer and he "hasn't had skin cancer" since getting the vaccination. On 14-FEB-2017 (reported as at the time of the call), the patient stated that his cancer was currently in stage 2 and that he still got lesions but did not have to get any skin biopsies or surgeries done since getting the GARDASIL. No treatment was prescribed for adverse event. No product quality complaint was involved. The outcome of the event was assessed as recovering/resolving. The reporter considered get rid of his stage 4 Leukemia cancer to be related to GARDASIL. Additional information has been requested.
COVID INFECTION; This spontaneous report received from a patient concerned a male of unspecified age. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine (suspension for injection, route of admin not reported, batch number: Unk) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On 08-SEP-2021, the patient experienced covid infection. Laboratory data included: COVID-19 virus test (NR: not provided) Positive. The action taken with covid-19 vaccine was not applicable. The patient had not recovered from covid infection. This report was non-serious.
This spontaneous report as received from a nurse refers to an unspecified number of patients of unknown age and gender. The nurse reported that on an unknown dates an unspecified number of patients received doses of RECOMBIVAX (route, dose, frequency and lot # not reported) that were improperly stored. No adverse experiences reported. No further information provided. This is one of several reports from the same source. Additional information has been requested.
Recipient developed very painful, swollen lymph node in axilla. 600mg ibuprofen administered at home by recipient and symptoms decreased. After the incident, the recipient recalled that she had received monoclonal antibody treatment after her COVID diagnosis in early September and forgot to mention that prior to receiving the booster vaccination. Symptoms lasted approximately 4 days.
A spontaneous report  was received from a consumer who was a pregnant, female patient of unknown age who received Moderna's COVID-19 Vaccine (mRNA-1273) and who experienced vaccine exposure during pregnancy.   There was no medical history and no relevant concomitant medications reported  On an unknown date in 2020, the patient received her first of two planned doses of mRNA-1273 (Lot # unknown) intramuscularly for prophylaxis of COVID-19 infection while.   The patient's estimated date of conception was not reported. The patient's due date was not reported. She wished to participate in the pregnancy registry.   Action taken with mRNA-1273 in response to the event was not reported.  The outcome event, vaccine exposure during pregnancy, was considered recovered/resolved.; Reporter's Comments: This is a case of product exposure during pregnancy with no associated AEs for this female patient. Patient will continue to be contacted for further monitoring of AEs during the pregnancy.
This spontaneous report as received from a physician via a company representative refers to an 11 year old male patient. No information regarding the patient's medical history or concurrent conditions was provided. On 18-FEB-2016, the patient was vaccinated with the third dose of GARDASIL 9 injection (lot# and expiry date were not reported), 0.5 ml intramuscularly, as well as with a dose of VAQTA injection (dose, route of administration, lot# and expiry date were not reported) and with an unspecified flu vaccine. There were no concomitant therapies reported. On 18-FEB-2016, reported as today, after getting his third dose of GARDASIL 9, the patient experienced syncope. The patient did not seek medical attention. The outcome of the event was reported as recovered on 18-FEB-2016, reported as today. The relatedness between suspect therapies and the event was not provided. Additional information is not expected as the reporting physician declined any further contact.
pt had a seizure lasting one minute with sequelae lasting 5-10 minutes.  This occurred 5 days after vaccination. He has never had a seizure in his life.
Dizziness; redness; large lump at injection site; nausea; chills; fatigue; This is a spontaneous report from a contactable consumer or other non hcp (patient). A 43-years-old non-pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: solution for injection) via an unspecified route of administration, administered in right arm on 11Mar2021 at 12:30 (batch/lot number was not reported) as dose 2, single for covid-19 immunization (age at vaccination was 43 years). Medical history included known allergies to Keflex and sulfa meds, autistic, asthmatic, bipolar disorder and endometriosis from an unknown date and unknown if ongoing. The concomitant medications were not reported. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) via an unspecified route of administration, administered in left arm on an unspecified date at 02:00 pm as single dose for COVID-19 immunization. The patient did not have COVID-19 prior to vaccination. Facility type vaccine was reported as hospital. It was reported that after receiving the second dose of vaccine on 12Mar2021 at 14:00 pm the patient experienced dizziness, redness, large lump at injection site, nausea, chills, fatigue. The patient did not test Covid post vaccination. The outcome of all the events was recovering at the time of report.   No follow up attempts are possible. Information about lot/batch number cannot been obtained.
FEVER; HEADACHE; A LOT OF PAIN AT INJECTION SITE; This spontaneous report received from a patient concerned a female of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805022 expiry: UNKNOWN) dose was not reported, administered on 18-MAR-2021 vaccinated on left arm for prophylactic vaccination. No concomitant medications were reported. On 18-MAR-2021, the subject experienced fever. On 18-MAR-2021, the subject experienced headache. On 18-MAR-2021, the subject experienced a lot of pain at injection site. Laboratory data included: Body temperature (NR: not provided) 101.4 F. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from a lot of pain at injection site on 18-MAR-2021, and had not recovered from fever, and headache. This report was non-serious.
pt recv vax 16DEC98 & pt awoke w/angioedema & urticaria; This is in follow-up to report(s) previously submitted on 03/01/1999. Information has been received from a physician concerning a 14-year-old Caucasian female patient with a history of urticaria who on 16-DEC-1999 was vaccinated with a first dose of RECOMBIVAX HB. The following morning, the patient awoke with angioedemia and urticara. Follow-up information from a physician reported that on 18-DEC-1998 the patient recovered.
This case was reported by a healthcare professional (office manager) and described the occurrence of injection site pain in a 47-year-old female subject who was vaccinated with BOOSTRIX (GlaxoSmithKline). On 26 March 2013 the subject received a dose of BOOSTRIX (.5 ml, unknown route, left deltoid). On 29 March 2013, 3 days after vaccination with BOOSTRIX, the subject experienced injection site pain (also described as "under arm pain"), injection site pruritus, swelling injection site, and injection site redness. This case was associated with a product quality complaint. The subject was seen by a physician and "diagnosed with erythema of about 3-4 centimeters in size." At the time of reporting the events were unresolved. The healthcare professional considered the events were probably related to vaccination with BOOSTRIX. The reporter documented 2 other cases with BOOSTRIX. See cases A1021182A and A1021180A for details on the other cases. Quality Assurance (QA) follow up was received on 23 May 2013. Based on the currently available safety information and the nature of the complaint, it can be concluded that there is no evidence for a safety signal concern for the batch AC52B100CA of BOOSTRIX and its similar batches. The OC investigation performed on the received samples shows that the complaint samples are conform to the specification for the description. GlaxoSmithKline Biologicals considers this complaint to be unsubstantiated.
seconds prior to administration, as the vaccine was heading towards the aimed injection site, the influenza vaccine liquids leaked out of the vial due to admin error of finer laying too heaving onto push lever. patient received most of the dose but very difficult to say how much leaked out.
pt recv vax;devel rxn characterized by reddened area,w/ rash,area about hand sized,affecting inject site & shoulder;
injected with Rotarix; This case was reported by a other health professional via call center representative and described the occurrence of inappropriate route of vaccination in a 4-month-old male patient who received Rota (Rotarix lyophilized formulation) (batch number 2x5l3, expiry date 15th July 2022) for prophylaxis.   Co-suspect products included rotavirus vaccine oral applicator device (Rotarix Oral Applicator Device) oral applicator for prophylaxis.   On 31st August 2021, the patient received Rotarix lyophilized formulation and Rotarix Oral Applicator Device. On 31st August 2021, unknown after receiving Rotarix lyophilized formulation and Rotarix Oral Applicator Device, the patient experienced inappropriate route of vaccination. On an unknown date, the outcome of the inappropriate route of vaccination was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: The health care professional reported that the patient was injected with Rotarix instead of oral administration, which led to inappropriate route of vaccination. No adverse event was reported. The reporter consented to follow up.
injection site swelling; Soreness at the injection site; Chronic Headache / headache; fever of 99.9 F; dry eyes; dry throat; Dry mouth; Not really chills, but feels like I'm gonna have chills; fatigue; muscle pain; stiff neck; This case was reported by a consumer via call center representative and described the occurrence of injection site swelling in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose in August 2021).   On 28th January 2022, the patient received the 2nd dose of Shingrix. In January 2022, less than a week after receiving Shingrix, the patient experienced injection site swelling, injection site pain, chronic headaches, fever, eye dryness, dry throat, dry mouth, feeling cold, fatigue, muscle pain and stiff neck. On an unknown date, the outcome of the injection site swelling, injection site pain, chronic headaches, fatigue, muscle pain and stiff neck were unknown and the outcome of the fever, eye dryness, dry throat, dry mouth and feeling cold were not recovered/not resolved.   It was unknown if the reporter considered the injection site swelling, injection site pain, chronic headaches, fever, eye dryness, dry throat, dry mouth, feeling cold, fatigue, muscle pain and stiff neck to be related to Shingrix.  Additional details were provided as follows: The patient self-reported this case. The age at vaccination was not reported. The patient stated, for the Shingrix vaccine, she was on her second dose. The patient stated she was running a fever of 99.9 Fahrenheit, she experienced headache which started 11 hours after taking the vaccine, soreness at the injection site, swelling, stiff neck, chronic headache, muscle pain, fatigue, she did not really had chills, but felt like she was going to have chills. The patient also experienced dry mouth, dry throat, dry eyes but she was drinking and that was it.  The reporter consented to follow up.
Tuesday within 1-2 hours of receiving vaccination. Throat closing, difficulty breathing, O2 saturation in the 80's, Tachy and HTN. Went to UC for treatment of Anaphylactic reaction following influenza vaccine
Received Anthrax and Typhoid in R arm @1030 am yesterday Around lunch time felt weak and start tingling with headache and shivers.
Patient received Moderna vaccination at 10am. Ten minutes after receiving the vaccine patient started to have seizure-like convulsions for 45 seconds to 1 minute. Patient regained consciousness, but remained very faint and ambulance was called. Patient was able to speak to give EMT symptoms and they took the patient to the hospital.
Uncontrollable high pitched screaming x 4-5 hrs; Illness lasted less than 1 day;